Lucid Diagnostics Inc. (NASDAQ: LUCD) is a Healthcare company (Medical - Devices) with a market capitalization of $78M. The Maz Rating grades it against the other companies in its sector.
Lucid Diagnostics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.40, Lucid Diagnostics Inc. trades at 13.7x sales and 12.3x book value. Over the last twelve months it generated about $6M of revenue and a net loss of $81M. It runs a gross margin of -20.6%, an operating margin of -941.7% and a net margin of -892.8%. It shows return on equity of -610.6%, return on invested capital of -209.7% and a free cash flow yield of -67.0%. On the balance sheet: a debt-to-equity ratio of 3.12 and a current ratio of 1.20. Over the past 52 weeks the share price ranged from $0.30 to $1.63, with a beta of 1.16.
Lucid Diagnostics Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Lucid Diagnostics Inc. (LUCD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 13.9% / 30% · (Cash+Inv) / Mkt Cap (36m) 14.5% / 30% · Interest income / Revenue 4.90% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 13.9% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 14.5% / 33% · Receivables / Mkt Cap (36m) 0.68% / 49% · Interest income / Revenue 4.90% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 13.9% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 14.5% / 33.33% · Receivables / Mkt Cap (24m) 0.68% / 33.33% · Interest income / Revenue 4.90% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 65.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 24612.4% / 33.33% · Receivables / Avg Assets (4Q) 2.31% / 33.33% · Interest income / Revenue 4.90% / 5% | Fail |
| FTSE | Debt / Total Assets 62.1% / 33.33% · (Cash+ST Inv) / Total Assets 64.6% / 33.33% · (Cash+Recv) / Total Assets 67.6% / 33.33% · Interest income / Revenue 4.90% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Lucid Diagnostics Inc. (LUCD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Lucid Diagnostics Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 4.90% of each dividend: Lucid Diagnostics Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.